 Type 2 inflammatory airway diseases such as asthma, chronic rhinosciositis, eosinophilic copte and allergic rhinitis are characterized by similar underlying mechanisms and can be treated using targeted therapies. These include anti-IGE, Illinois 505R, Illinois 4R antibody therapy, Restlazumab, Benrolizumab, Jupilumab and Tezapelumab. These therapies have been shown to improve patient outcomes and reduce disease burden. This article was authored by Jorge Maspero, Yocchi Adir, Mona Alamod and others.